Skip to Content
Merck
All Photos(1)

Key Documents

SHC012

Sigma-Aldrich

MISSION® pLKO.1-puro-CMV-TagRFP Positive Control Plasmid DNA

Contains a gene encoding TagRFP

Synonym(s):

MISSION® Control Vectors

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
41106609
NACRES:
NA.51

product line

MISSION®

concentration

500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)

shipped in

dry ice

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

General description

Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, we recommend producing self-inactivating replication incompetent viral particles in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The CMV-TagRFP Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.

Application

To see more application data, protocols, vector maps visit sigma.com/shrna.
The MISSION TagRFP Control Vector is an 8594 base pair lentivirus plasmid vector that contains a gene encoding TagRFP, under the control of the CMV promoter. The CMV-TagRFP Control Vector is useful as a positive control in experiments using the MISSION shRNA library clones.

Legal Information

Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
TagRFP is a trademark of Evrogen Co.

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chi Huu Nguyen et al.
Scientific reports, 9(1), 9139-9139 (2019-06-27)
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular basis and to patients´ outcome. Clinical, cytogenetic, and mutational data are used to classify patients into risk groups with different survival, however, within-group heterogeneity is

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service